CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens

Bone Marrow Transplantation
T L HolyoakeI M Franklin

Abstract

We have previously demonstrated that CD34+ cells, selected from peripheral blood progenitor cells (PBPC), can be expanded in ex vivo culture and can be infused in tandem with unmanipulated PBPC with little or no toxicity. In this study, four patients (two non-Hodgkin's lymphoma (NHL), two multiple myeloma (MM)) received myeloablative conditioning prior to stem cell rescue using ex vivo expanded cells alone. The two patients with NHL received cyclophosphamide and total body irradiation (CY/TBI) and the two patients with MM, busulphan and melphalan (Bu/M). One case received an inadequate CFU-GM dose, despite expansion, and in one case the expanded cells were contaminated. No definitive conclusions may therefore be drawn concerning engraftment in these two cases. However, the other two cases received high doses of committed progenitors. Following infusion of the expanded material, all four patients failed to show sustained neutrophil engraftment and none showed evidence of platelet engraftment. Back-up, unmanipulated PBPC were therefore infused on days 14, 34, 32 and 28 and subsequently all four cases achieved satisfactory engraftment of both neutrophils and platelets. In conclusion, we feel that, CD34+ cells, expanded ex vivo usi...Continue Reading

Citations

Sep 30, 2000·Stem Cells·L KanzS Scheding
Dec 1, 2011·International Journal of Hematology·Ana-María Perdomo-Arciniegas, Jean-Paul Vernot
May 26, 1999·Experimental Hematology·D S DonnellyD S Krause
Oct 2, 1998·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·S Fetscher, R Mertelsmann
Nov 13, 2008·Cytotechnology·Andrew D ClarkTessa L Holyoake
Oct 6, 2009·Bone Marrow Transplantation·S S KellyE Shpall
Sep 6, 2000·Journal of Internal Medicine·G Gahrton, B Björkstrand
Nov 20, 2002·Vox Sanguinis·P H Roddie, M L Turner
Nov 25, 2000·Journal of Hematotherapy & Stem Cell Research·C C ShihS J Forman
Jan 5, 2000·The Journal of Clinical Investigation·D Y JoM A Moore
May 25, 2011·World Journal of Stem Cells·Zoran Ivanovic
Oct 24, 2000·Leukemia & Lymphoma·T WatanabeY Takaue
Jul 2, 2005·Expert Opinion on Emerging Drugs·Nnenna Osuji, R Pettengell
Sep 15, 2010·Best Practice & Research. Clinical Haematology·S S TungE J Shpall
Mar 4, 2010·Cytotherapy·Susan Staba KellyElizabeth Shpall
Nov 26, 2009·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·Z Ivanovic, J-M Boiron
Aug 17, 2004·Experimental Hematology·J M Brown, I L Weissman
Jan 1, 1999·Cytotherapy·C M VerfaillieUNKNOWN Stem Cell Evaluation and Manipulation Committee

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.